Navigation Links
Accelerated search for active agents to treat Alzheimer's and Parkinson's
Date:2/24/2012

Professor Erich Wanker of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch and of the Excellence Cluster Neurocure is to receive EUR 675 000 in funding from the Helmholtz Association over the next two years. The grant shall be used to accelerate the search for active agents to treat diseases that are caused by protein misfolding. These include Alzheimer's and Parkinson's. The grant amount will be matched by the MDC, a member institution of the Helmholtz Association, which means that the total funding for the research project will be EUR 1.35 million.

The grant shall be used to develop a standardized screening platform for the identification of active agents that can be utilized by the pharmaceutical industry. The project is intended to result in the establishment of a spin-off company. The key element will be a system to identify active agents that impact protein aggregates that are toxic for brain cells. Protein aggregation plays a significant role in common neurological diseases such as Alzheimer's and Parkinson's or the rare Huntington's disease. In the pathogenesis of these diseases, a misfolding of specific proteins occurs in the brain cells, leading to an aggregation of harmful structures that cannot be disposed of. This increasingly leads to degeneration of the brain cells in the affected individuals and subsequently depending on the protein and the disease to memory loss, movement disorders, psychosis and dementia. Altogether, about 40 diseases can be attributed to protein misfolding, including diabetes mellitus.

The research group of Professor Wanker has been studying protein misfolding for over ten years and has developed innovative concepts and methods to test active agents for their capacity to intervene in protein misfolding processes. One of the group's discoveries is that epigallocatechin-3-gallate (EGCG), a green tea extract, binds to toxic misfolded products and modulates these into nontoxic structures.

The methods hitherto used by the group shall now be incorporated into a technology platform to test larger libraries of potential active agents. This will include a high-throughput robotic system developed by the researchers for investigating interactions among proteins but also between proteins and other substances. In 2008 they received the Erwin Schrdinger Prize for research in this area.

The new Helmholtz Validation Fund, according to the Helmholtz Association announcement, will also fund a project of the Helmholtz Center Dresden-Rossendorf and the Research Center Jlich. The aim of this project is to improve imaging techniques for drug development to treat Alzheimer's.

Until 2015 the Initiative and Networking Fund of the Helmholtz Association has allocated a total of EUR 26 million to the Helmholtz Validation Fund to fund projects at Helmholtz centers. Including the matching funds from the centers, more than EUR 50 million will be available for technology transfer projects.


'/>"/>

Contact: Barbara Bachtler
bachtler@mdc-berlin.de
49-309-406-3896
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Concordia research accelerated
2. Accelerated lab evolution of biomolecules could yield new generation of medicines
3. Study finds link between chronic depression and accelerated immune cell aging
4. New year, new vitamin C discovery: It cures mice with accelerated aging disease
5. Geological cycle causes biodiversity booms and busts every 60 million years, research suggests
6. UC Santa Barbara researchers new study may lead to MRIs on a nanoscale
7. Research examines environmental triggers altering gene function in CFS patients
8. Researchers discover how vitamin D inhibits inflammation
9. Study finds college students willing to donate genetic material to biobanks for research
10. Purdue researchers reveal role of protein mutation in Parkinsons disease
11. Engineering, geoscience faculty help lead $3 million NSF Delta research collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/12/2017)... 2017  New research undertaken by Fit Small Business ... 1,000 participants were simply asked which office technology had they ... consider standard issue.  Insights on what will be ... from futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... ... January 17, 2017 , ... ... Rheumatoid Factor (RF) to its VALIDATE® SP2 calibration verification / linearity test kit. ... human serum base. Each VALIDATE® SP2 kit is prepared using the CLSI recommended ...
(Date:1/17/2017)... ... January 17, 2017 , ... MS Technologies™ and ... Balance™ GT Soybean Performance System will combine industry-leading genetics with a double herbicide-tolerant ... the new Balance® Bean herbicide. The Balance™ GT Soybean Performance System will benefit ...
(Date:1/17/2017)... Jan. 17, 2017 The Global Implantable ... CAGR of around 7.5% over the next decade ... of the prominent trends that the market is ... diseases & graft transplant surgeries and medical implants ... market is categorized into immunomodulatory biomaterials, natural, polymers, ...
(Date:1/17/2017)...  An international team of researchers from UC ... Hospital Albrechtsen Research Centre/University of Manitoba have identified ... need affecting nearly one in 15 Americans. Published ... results identify small molecule drugs with neuroprotective and ... in animal models of metabolic, chemical and infection ...
Breaking Biology Technology: